Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Oscar Lopez de la Fuente"'
Autor:
Michaela Gruber, Martin Hilgarth, Stefan Kubicek, Edit Porpaczy, Christian Schmidl, Rainer Hubmann, Nikolaus Krall, Anna Ringler, Philipp B. Staber, Christina Taubert, Mohammad Araghi, Dita Demirtas, Gregory I. Vladimer, Oscar Lopez de la Fuente, Medhat Shehata, Giulio Superti-Furga, Berend Snijder, Gregor Hoermann, Tea Pemovska, Cathrin Skrabs, Thomas Krausgruber, Kathrin Runggatscher, Ulrich Jäger, Susanne Schnabl, André F. Rendeiro, Christoph Bock
Publikováno v:
Nature Chemical Biology, 15 (3)
Nature Chemical Biology
Nature Chemical Biology
The Bruton tyrosine kinase (BTK) inhibitor ibrutinib has substantially improved therapeutic options for chronic lymphocytic leukemia (CLL). Although ibrutinib is not curative, it has a profound effect on CLL cells and may create new pharmacologically
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee8ec57ac57f9b814e4af6f250e81781
https://hdl.handle.net/20.500.11850/328366
https://hdl.handle.net/20.500.11850/328366
Autor:
Johannes W. Bigenzahn, Lukas Kenner, Berend Snijder, Nicole Prutsch, Ulrich Jäger, Philipp B. Staber, Gregory I. Vladimer, Marius E. Mayerhoefer, Hye-Soo Choi, Giulio Superti-Furga, Anna Ringler, Katsuhiro Miura, Gerald W. Prager, Monika Sabler, Katharina Ocko, Ingrid Simonitsch-Klupp, Nikolaus Krall, Georg Jeryczynski, Ann-Sofie Schmolke, Heinz Gisslinger, Lukas Kazianka, Stefan Kubicek, Peter Valent, Oscar Lopez de la Fuente, Sinan Gültekin, Leonhard Müllauer, Emiel van der Kouwe, Gregor Hoermann, Robert Kralovics, Wolfgang R. Sperr, Belgin Korkmaz, Christoph Kornauth, F. X. Felberbauer, Olaf Merkel
Publikováno v:
The Lancet Haematology
The Lancet Haematology, 4 (12)
The Lancet Haematology, 4 (12)
Background Patients with refractory or relapsed haematological malignancies have few treatment options and short survival times. Identification of effective therapies with genomic-based precision medicine is hampered by intratumour heterogeneity and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::125ea7d94188049919a220fe2d6f8b6b
Autor:
Thomas Helleday, Monika Sabler, Kumar Sanjiv, Gregory I. Vladimer, Ulrich Jäger, Paul Knöbl, Berend Snijder, Kilian Huber, Giulio Superti-Furga, Nikolaus Krall, Charles-Hugues Lardeau, Anna Ringler, Oscar Lopez de la Fuente, Johannes W. Bigenzahn, Stefan Kubicek, Ulrika Warpman Berglund
Publikováno v:
Nature Chemical Biology
Small-molecule drugs may complement antibody-based therapies in an immune-oncology setting, yet systematic methods for the identification and characterization of the immunomodulatory properties of these entities are lacking. We surveyed the immumomod
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ac7c96059e54c9fc56076180f9a9194
Autor:
Ulrich Jaeger, Susanne Schnabl, Thomas Krausgruber, Philipp B. Staber, Gregory I. Vladimer, Christian Schmidl, Edit Porpaczy, Medhat Shehata, Dita Demirtas, Berend Snijder, Michaela Gruber, Tea Pemovska, Stefan Kubicek, Andre Renderio, Giulio Superti-Furga, Oscar Lopez de la Fuente, Rainer Hubmann, Gregor Hoermann, Martin Hilgrath, Christoph Bock, Anna Ringler, Cathrin Skrabs, Mohammad Araghi, Nikolaus Krall
Publikováno v:
Blood. 130:800-800
Chronic lymphocytic leukemia (CLL) is characterized by clonal proliferation and accumulation of malignant B lymphocytes in the blood, bone marrow, spleen, and lymph nodes. This process is associated with constitutively activated B cell receptor (BCR)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::64c610d77ba1721632dfc75928c42c8a
https://doi.org/10.1182/blood.v130.suppl_1.800.800
https://doi.org/10.1182/blood.v130.suppl_1.800.800
Autor:
Giulio Superti-Furga, Olaf Merkel, Lukas Kenner, Nicole Prutsch, Stefan Kubicek, Peter Valent, Philipp B. Staber, Gregory I. Vladimer, Christoph Kornauth, Anna Ringler, Nikolaus Krall, Johannes W. Bigenzahn, Belgin Korkmaz, Gerald W. Prager, F. X. Felberbauer, Berend Snijder, Lukas Kazianka, Marius E. Mayerhoefer, Robert Kralovics, Georg Jeryczynski, Ann-Sofie Schmolke, Katsuhiro Miura, Heinz Gisslinger, Ingrid Simonitsch-Klupp, Oscar Lopez de la Fuente, Leonhard Muellauer, Gregor Hoermann, Wolfgang R. Sperr, Emiel van der Kouwe, Ulrich Jaeger, Hye-Soo Choi
Publikováno v:
Web of Science
Background. Patients with aggressive hematologic malignancies failing at least two lines of therapy are without further standard treatment options and have a poor prognosis. Identifying effective therapies with genomic-based precision medicine is ham
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f98523f962100eb00d891c8f91d9a9f
https://doi.org/10.1182/blood.v130.suppl_1.855.855
https://doi.org/10.1182/blood.v130.suppl_1.855.855